ADPT (Adaptive Biotechnologies) Equivalent Admissions #: 0.00 (As of Mar. 2026)

What is Adaptive Biotechnologies Equivalent Admissions #?

Adaptive Biotechnologies ADPT -3.17% 67 Equivalent Admissions # is 0.00 as of Mar. 2026. GuruFocus rates ADPT with a GF Score™ of 67/100 and a GF Value™ of $10.05 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for Adaptive Biotechnologies's Equivalent Admissions # or its related term are showing as below:

ADPT's Equivalent Admissions # is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

Adaptive Biotechnologies Equivalent Admissions # Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Equivalent Admissions # Chart

Adaptive Biotechnologies Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Dec25

Equivalent Admissions #

Get a 7-Day Free Trial

No of Surgeries Procedures #

Get a 7-Day Free Trial

Adaptive BiotechnologiesQuarterly Data

Trend

Dec21

Mar22

Jun22

Sep22

Dec22

Mar23

Jun23

Sep23

Dec23

Mar24

Jun24

Sep24

Dec24

Mar25

Jun25

Sep25

Dec25

Mar26

Equivalent Admissions #

Get a 7-Day Free Trial

No of Surgeries Procedures #

Get a 7-Day Free Trial

ADPT vs GRAL, WGS, RDNT: Equivalent Admissions # Comparison

For the Diagnostics & Research subindustry, Adaptive Biotechnologies's Equivalent Admissions #, along with its competitors' market caps and Equivalent Admissions # data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

67GF Score

Adaptive Biotechnologies Corp ADPT

Equivalent Admissions # is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Frequently Asked Questions

What does a Equivalent Admissions # of 0.00 mean?

Adaptive Biotechnologies (ADPT) has a Equivalent Admissions # of 0.00 as of Mar. 2026. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Adaptive Biotechnologies and its competitors.

Is Adaptive Biotechnologies' Equivalent Admissions # too high?

Adaptive Biotechnologies' current Equivalent Admissions # is 0.00. Overall, Adaptive Biotechnologies has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Adaptive Biotechnologies' Equivalent Admissions # compare to GRAL and WGS?

Adaptive Biotechnologies' Equivalent Admissions # of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Equivalent Admissions # for a Medical Diagnostics & Research company?

A good Equivalent Admissions # depends on the Medical Diagnostics & Research industry context. However, Equivalent Admissions # should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Equivalent Admissions # mean?

A high Equivalent Admissions # can signal that a stock is expensive relative to its fundamentals. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Equivalent Admissions # is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Adaptive Biotechnologies stock overvalued right now?

Based on GuruFocus' analysis, Adaptive Biotechnologies (ADPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.05, compared to a current price of $20.16 — trading 100.6% above its estimated fair value. The current Equivalent Admissions # is 0.00. Adaptive Biotechnologies' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Equivalent Admissions # calculated?

Equivalent Admissions # is calculated from a company's financial statements. For Adaptive Biotechnologies (ADPT), the current Equivalent Admissions # is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (ADPT) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of $20.16 is trading 100.6% above its estimated GF Value™ of $10.05. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for ADPT:

Equivalent Admissions #: 0.00
GF Value™: $10.05 vs. price of $20.16 (100.6% above fair value)
GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the ADPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies GRAL WGS RDNT VCYT NEO SHC CDNA PSNL BLLN OPK TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Other Exchanges 1HM:Germany

Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

67GF Score

Get the complete analysis for ADPT

Equivalent Admissions # is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.16

Price

$10.05

GF Value

View ADPT Analysis